X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (177) 177
Publication (35) 35
Conference Proceeding (15) 15
Book Review (13) 13
Book / eBook (11) 11
Newspaper Article (3) 3
Dissertation (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (111) 111
humans (108) 108
oncology (98) 98
female (84) 84
middle aged (72) 72
aged (55) 55
adult (43) 43
chemotherapy (43) 43
breast neoplasms - drug therapy (41) 41
male (40) 40
antineoplastic combined chemotherapy protocols - therapeutic use (37) 37
cancer (33) 33
treatment outcome (28) 28
breast cancer (26) 26
chemotherapy, adjuvant (26) 26
disease-free survival (24) 24
antineoplastic combined chemotherapy protocols - adverse effects (23) 23
bevacizumab (23) 23
aged, 80 and over (22) 22
breast neoplasms - pathology (21) 21
therapy (21) 21
fluorouracil (19) 19
antibodies, monoclonal - adverse effects (18) 18
antibodies, monoclonal, humanized (18) 18
article (17) 17
neoplasm staging (17) 17
clinical trials (16) 16
drug therapy (16) 16
medicine, general & internal (16) 16
original reports (15) 15
tamoxifen (15) 15
abridged index medicus (14) 14
analysis (14) 14
antibodies, monoclonal - administration & dosage (14) 14
trastuzumab (14) 14
breast neoplasms - mortality (13) 13
follow-up studies (13) 13
leucovorin (13) 13
research (13) 13
survival (13) 13
trial (13) 13
care and treatment (12) 12
cyclophosphamide - administration & dosage (12) 12
docetaxel (12) 12
double-blind method (12) 12
doxorubicin - administration & dosage (12) 12
fluorouracil - administration & dosage (12) 12
kaplan-meier estimate (12) 12
quality of life (12) 12
randomized-trial (12) 12
surgery (12) 12
survival rate (12) 12
united states (12) 12
women (12) 12
antibodies, monoclonal - therapeutic use (11) 11
colorectal neoplasms - drug therapy (11) 11
proportional hazards models (11) 11
taxoids - administration & dosage (11) 11
adjuvant treatment (10) 10
antineoplastic agents, hormonal - therapeutic use (10) 10
breast neoplasms - surgery (10) 10
colorectal cancer (10) 10
colorectal neoplasms - pathology (10) 10
drug administration schedule (10) 10
expression (10) 10
health aspects (10) 10
leucovorin - administration & dosage (10) 10
metastasis (10) 10
paclitaxel (10) 10
survival analysis (10) 10
antibodies, monoclonal, humanized - administration & dosage (9) 9
carcinoma (9) 9
dose-response relationship, drug (9) 9
hematology, oncology and palliative medicine (9) 9
metastatic colorectal-cancer (9) 9
monoclonal antibodies (9) 9
multicenter (9) 9
neoplasm metastasis (9) 9
postmenopausal women (9) 9
prognosis (9) 9
risk (9) 9
surgical adjuvant breast (9) 9
tamoxifen - therapeutic use (9) 9
1st-line treatment (8) 8
antineoplastic agents - therapeutic use (8) 8
cells (8) 8
combined modality therapy (8) 8
fluorouracil - adverse effects (8) 8
health maintenance organizations (8) 8
medicine & public health (8) 8
open-label (8) 8
paclitaxel - administration & dosage (8) 8
tumors (8) 8
adjuvant chemotherapy (7) 7
angiogenesis (7) 7
animals (7) 7
antimitotic agents (7) 7
antineoplastic agents (7) 7
antineoplastic agents - administration & dosage (7) 7
antineoplastic combined chemotherapy protocols - administration & dosage (7) 7
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (4) 4
UTL at Downsview - May be requested (3) 3
St. Michael's College (John M. Kelly) - 2nd Floor (2) 2
Engineering & Comp. Sci. - Reference (1) 1
Gerstein Science - Stacks (1) 1
Robarts - Reference (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10030, pp. 1837 - 1846
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 12, pp. 1183 - 1192
Summary Background We studied the effect on tumour response to neoadjuvant therapy of the substitution of lapatinib for trastuzumab in combination with weekly... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | WOMEN | CELLS | SURGICAL ADJUVANT BREAST | PREOPERATIVE CHEMOTHERAPY | ONCOLOGY | GW572016 | CHEMOTHERAPY PLUS TRASTUZUMAB | PERTUZUMAB | INHIBITOR | DOCETAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Puerto Rico | United States | Humans | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Breast Neoplasms - enzymology | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Biomarkers, Tumor - metabolism | Mastectomy | Female | Neoadjuvant Therapy | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Odds Ratio | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Drug Administration Schedule | Logistic Models | Treatment Outcome | Chi-Square Distribution | Breast Neoplasms - drug therapy | Canada | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Quinazolines - adverse effects | Trastuzumab | Health maintenance organizations | Neoadjuvant therapy | Medical colleges | Care and treatment | Cyclophosphamide | Anthracyclines | Adjuvant treatment | Breast cancer | Product development | Public health | Cancer | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 387, Issue 10021, pp. 849 - 856
Summary Background Ductal carcinoma in situ is currently managed with excision, radiotherapy, and adjuvant hormone therapy, usually tamoxifen. We postulated... 
Internal Medicine | INTRADUCTAL BREAST-CANCER | MEDICINE, GENERAL & INTERNAL | SURGICAL ADJUVANT BREAST | RADIATION-THERAPY | B-17 | Breast Neoplasms - surgery | Triazoles - administration & dosage | Triazoles - adverse effects | Thrombosis - chemically induced | Age Factors | Humans | Middle Aged | Tamoxifen - administration & dosage | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Carcinoma, Ductal, Breast - drug therapy | Mastectomy, Segmental | Antineoplastic Agents, Hormonal - therapeutic use | Postmenopause | Female | Embolism - chemically induced | Aromatase Inhibitors - therapeutic use | Triazoles - therapeutic use | Aromatase Inhibitors - administration & dosage | Carcinoma, Ductal, Breast - surgery | Double-Blind Method | Administration, Oral | Antineoplastic Agents, Hormonal - administration & dosage | Combined Modality Therapy | Breast Neoplasms - drug therapy | Breast Neoplasms - radiotherapy | Carcinoma, Ductal, Breast - radiotherapy | Tamoxifen - therapeutic use | Tamoxifen - adverse effects | Nitriles - adverse effects | Nitriles - therapeutic use | Lumpectomy | Medical colleges | Carcinoma | Radiation | Clinical trials | Postmenopausal women | Hormones | Tamoxifen | Radiotherapy | Biometry | Health maintenance organizations | Product development | Cancer | Chemotherapy | Womens health | Older people | Breast cancer | Radiation therapy | Cancer surgery | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 9, pp. 1037 - 1048
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 10, pp. 997 - 1005
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2018, Volume 379, Issue 8, pp. 753 - 763
Journal Article